BioMarin Appoints Timothy Walbert to Board of Directors

BioMarin Pharmaceutical has announced the appointment of Timothy P. Walbert to its Board of Directors, effective February 24, 2025. Walbert, former chairman and CEO of Horizon Therapeutics, brings over 30 years of leadership in biopharmaceuticals, having played key roles in companies like Amgen, AbbVie, and Pfizer. His experience in commercializing medicines and driving strategic growth makes him a valuable addition as BioMarin continues its mission of delivering breakthrough therapies for genetically defined conditions.

Alexander Hardy, BioMarin’s president and CEO, highlighted Walbert’s deep industry expertise and commitment to patient-centered innovation. "Tim’s proven leadership in bringing life-changing treatments to market aligns perfectly with our vision," said Hardy. Walbert, currently a senior advisor at Amgen, expressed enthusiasm about joining BioMarin at a pivotal time. "I look forward to contributing to BioMarin’s focus on innovation, growth, and value creation while keeping patients at the center of everything we do," he shared.